Skip to main content
Erschienen in: Hepatology International 2/2021

16.04.2021 | Original Article

Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan

verfasst von: Naruhiro Kimura, Masaaki Takamura, Nobutaka Takeda, Yusuke Watanabe, Yoshihisa Arao, Masahumi Takatsuna, Suguru Takeuchi, Hiroyuki Abe, Toru Setsu, Hiroteru Kamimura, Akira Sakamaki, Kenya Kamimura, Atsunori Tsuchiya, Shuji Terai

Erschienen in: Hepatology International | Ausgabe 2/2021

Einloggen, um Zugang zu erhalten

Abstract

Background

Biochemical response to treatment in patients with primary biliary cholangitis (PBC) reflects prognosis. However, the best predictive criteria to detect biochemical response remain undetermined. In addition, because these criteria need > 6 months until definition, parameters that can estimate its results before initiating treatment are needed.

Methods

We conducted a single-center retrospective study on 196 patients with PBC, followed up for at least 12 months after initiating treatment.

Results

Kaplan–Meier analysis showed that Paris II (p = 0.002) and Rotterdam criteria (p = 0.001) could estimate the overall survival of PBC patients, whereas Paris II (p = 0.001), Rotterdam (p = 0.001), and Rochester criteria (p= 0.025) could estimate liver-related deaths. Cox hazard analysis revealed Paris II and Rotterdam criteria as significantly independent predictors of overall survival (hazard ratio (HR) 3.948, 95% CI 1.293–12.054, p = 0.016 and HR 6.040, 95% CI 1.969–18.527, p = 0.002, respectively) and liver-related deaths (HR 10.461, 95% CI 1.231–88.936, p = 0.032 and HR 10.824, 95% CI 1.252–93.572, p = 0.032, respectively). The results of Paris II criteria could be estimated by serum prothrombin time (Odds ratio (OR) 1.052, 95% CI 1.008–1.098, p = 0.021) and alanine transaminase level (OR 0.954, 95% CI 0.919–0.991, p = 0.014) whereas, those of Rotterdam criteria could be estimated by serum albumin level (OR 3.649, 95% CI 1.098–12.128, p = 0.035) at the time of diagnosis.

Conclusions

This study highlights the best prediction criteria and pre-treatment parameters that facilitate the prognosis of PBC patients.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6:25906.CrossRef Lleo A, Jepsen P, Morenghi E, Carbone M, Moroni L, Battezzati PM, et al. Evolving trends in female to male incidence and male mortality of primary biliary cholangitis. Sci Rep. 2016;6:25906.CrossRef
2.
Zurück zum Zitat Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;2013(144):560–9.CrossRef Carbone M, Mells GF, Pells G, Dawwas MF, Newton JL, Heneghan MA, et al. Sex and age are determinants of the clinical phenotype of primary biliary cirrhosis and response to ursodeoxycholic acid. Gastroenterology. 2013;2013(144):560–9.CrossRef
3.
Zurück zum Zitat Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;2014(147):1338–49.CrossRef Lammers WJ, van Buuren HR, Hirschfield GM, Janssen HL, Invernizzi P, Mason AL, et al. Levels of alkaline phosphatase and bilirubin are surrogate end points of outcomes of patients with primary biliary cirrhosis: an international follow-up study. Gastroenterology. 2014;2014(147):1338–49.CrossRef
4.
Zurück zum Zitat Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;2016(65):321–9.CrossRef Trivedi PJ, Lammers WJ, van Buuren HR, Pares A, Floreani A, Janssen HL, et al. Stratification of hepatocellular carcinoma risk in primary biliary cirrhosis: a multicentre international study. Gut. 2016;2016(65):321–9.CrossRef
5.
Zurück zum Zitat Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;2009(50):291–308.CrossRef Lindor KD, Gershwin ME, Poupon R, Kaplan M, Bergasa NV, Heathcote EJ. Primary biliary cirrhosis. Hepatology. 2009;2009(50):291–308.CrossRef
6.
Zurück zum Zitat European Association for the Study of Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;2009(51):237–67.CrossRef European Association for the Study of Liver. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol. 2009;2009(51):237–67.CrossRef
7.
Zurück zum Zitat ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044–50.CrossRef ter Borg PC, Schalm SW, Hansen BE, van Buuren HR, Dutch PBC Study Group. Prognosis of ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol. 2006;101:2044–50.CrossRef
8.
Zurück zum Zitat Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;2006(101):1529–38.CrossRef Shi J, Wu C, Lin Y, et al. Long-term effects of mid-dose ursodeoxycholic acid in primary biliary cirrhosis: a meta-analysis of randomized controlled trials. Am J Gastroenterol. 2006;2006(101):1529–38.CrossRef
9.
Zurück zum Zitat Corpechot C, Carrat F, Poupon R. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;2002(122):652–8.CrossRef Corpechot C, Carrat F, Poupon R. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology. 2002;2002(122):652–8.CrossRef
10.
Zurück zum Zitat Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–43.CrossRef Nevens F, Andreone P, Mazzella G, Strasser SI, Bowlus C, Invernizzi P, et al. A placebo-controlled trial of obeticholic acid in primary biliary cholangitis. N Engl J Med. 2016;375:631–43.CrossRef
11.
Zurück zum Zitat Shinji I, Hiromasa O, Shuhei N, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;2008(38):557–64. Shinji I, Hiromasa O, Shuhei N, Zeniya M, Kaneko S, Onji M, et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: a prospective, multicenter study. Hepatol Res. 2008;2008(38):557–64.
12.
Zurück zum Zitat Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, et al. Bezafibrate improves GLOBE and UK-PBC score and long-term outcomes in patients with PBC. Hepatology. 2019;2019(70):2035–46.CrossRef Honda A, Tanaka A, Kaneko T, Komori A, Abe M, Inao M, et al. Bezafibrate improves GLOBE and UK-PBC score and long-term outcomes in patients with PBC. Hepatology. 2019;2019(70):2035–46.CrossRef
13.
Zurück zum Zitat Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;2006(130):715–20. CrossRef Pares A, Caballeria L, Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic acid. Gastroenterology. 2006;2006(130):715–20. CrossRef
14.
Zurück zum Zitat Edith M, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJM, Haagsma EB, et al. Improved prognosis of patient with PBC that have a biochemical response to UDCA. Gastroenterology. 2009;2009(136):1281–7. Edith M, Hansen BE, de Vries RA, den Ouden-Muller JW, van Ditzhuijsen TJM, Haagsma EB, et al. Improved prognosis of patient with PBC that have a biochemical response to UDCA. Gastroenterology. 2009;2009(136):1281–7.
15.
Zurück zum Zitat Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;2008(48):871–7.CrossRef Corpechot C, Abenavoli L, Rabahi N, Chretien Y, Andreani T, Johanet C, et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology. 2008;2008(48):871–7.CrossRef
16.
Zurück zum Zitat Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;1999(19):115–21.CrossRef Angulo P, Lindor KD, Therneau TM, Jorgensen RA, Malinchoc M, Kamath PS, et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver. 1999;1999(19):115–21.CrossRef
17.
Zurück zum Zitat Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009;2009(44):630–4.CrossRef Azemoto N, Abe M, Murata Y, Hiasa Y, Hamada M, Matsuura B, et al. Early biochemical response to ursodeoxycholic acid predicts symptom development in patients with asymptomatic primary biliary cirrhosis. J Gastroenterol. 2009;2009(44):630–4.CrossRef
18.
Zurück zum Zitat Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;2015(149):1804–12.CrossRef Lammers WJ, Hirschfield GM, Corpechot C, Nevens F, Lindor KD, Janssen HL, et al. Development and validation of a scoring system to predict outcomes of patients with primary biliary cirrhosis receiving ursodeoxycholic acid therapy. Gastroenterology. 2015;2015(149):1804–12.CrossRef
19.
Zurück zum Zitat Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UKPBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology. 2016;2016(63):930–50.CrossRef Carbone M, Sharp SJ, Flack S, Paximadas D, Spiess K, Adgey C, et al. The UKPBC risk scores: Derivation and validation of a scoring system for long-term prediction of end-stage liver disease in primary biliary cirrhosis. Hepatology. 2016;2016(63):930–50.CrossRef
21.
Zurück zum Zitat Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;2006(43):1317–25.CrossRef Sterling RK, Lissen E, Clumeck N, Sola R, Correa MC, Montaner J, et al. Development of a simple noninvasive index to predict significant fibrosis in patients with HIV/HCV coinfection. Hepatology. 2006;2006(43):1317–25.CrossRef
22.
Zurück zum Zitat Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;2003(38):518–26.CrossRef Wai CT, Greenson JK, Fontana RJ, Kalbfleisch JD, Marrero JA, Conjeevaram HS, et al. A simple noninvasive index can predict both significant fibrosis and cirrhosis in patients with chronic hepatitis C. Hepatology. 2003;2003(38):518–26.CrossRef
23.
Zurück zum Zitat Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Benson JT, Krom RA. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transplant. 2001;2001(6):489–94. Kim WR, Wiesner RH, Poterucha JJ, Therneau TM, Benson JT, Krom RA. Adaptation of the Mayo primary biliary cirrhosis natural history model for application in liver transplant candidates. Liver Transplant. 2001;2001(6):489–94.
24.
Zurück zum Zitat Kim WR, Wiesner RH, Therneau TM, Poterucha JJ, Porayko MK, Evans RW, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology. 1998;1998(28):33–8.CrossRef Kim WR, Wiesner RH, Therneau TM, Poterucha JJ, Porayko MK, Evans RW, et al. Optimal timing of liver transplantation for primary biliary cirrhosis. Hepatology. 1998;1998(28):33–8.CrossRef
25.
Zurück zum Zitat Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;2018(3):626–34.CrossRef Carbone M, Nardi A, Flack S, Carpino G, Varvaropoulou N, Gavrila C, et al. Pretreatment prediction of response to ursodeoxycholic acid in primary biliary cholangitis: development and validation of the UDCA Response Score. Lancet Gastroenterol Hepatol. 2018;2018(3):626–34.CrossRef
26.
Zurück zum Zitat Hiramatsu K, Aoyama H, Zen Y, et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology. 2006;2006(49):466–78.CrossRef Hiramatsu K, Aoyama H, Zen Y, et al. Proposal of a new staging and grading system of the liver for primary biliary cirrhosis. Histopathology. 2006;2006(49):466–78.CrossRef
27.
Zurück zum Zitat Nakanuma Y, Zen Y, Harada K, Aishima S, Kitagawa S, Nakanumaet Y. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010;2010(60):167–74.CrossRef Nakanuma Y, Zen Y, Harada K, Aishima S, Kitagawa S, Nakanumaet Y. Application of a new histological staging and grading system for primary biliary cirrhosis to liver biopsy specimens: Interobserver agreement. Pathol Int. 2010;2010(60):167–74.CrossRef
Metadaten
Titel
Paris II and Rotterdam criteria are the best predictors of outcomes in patients with primary biliary cholangitis in Japan
verfasst von
Naruhiro Kimura
Masaaki Takamura
Nobutaka Takeda
Yusuke Watanabe
Yoshihisa Arao
Masahumi Takatsuna
Suguru Takeuchi
Hiroyuki Abe
Toru Setsu
Hiroteru Kamimura
Akira Sakamaki
Kenya Kamimura
Atsunori Tsuchiya
Shuji Terai
Publikationsdatum
16.04.2021
Verlag
Springer India
Erschienen in
Hepatology International / Ausgabe 2/2021
Print ISSN: 1936-0533
Elektronische ISSN: 1936-0541
DOI
https://doi.org/10.1007/s12072-021-10163-0

Weitere Artikel der Ausgabe 2/2021

Hepatology International 2/2021 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.